Despite this controversy, most data agree that ER-positive/ PR-negative or low breast cancers align with the genomic luminal B sub-type and are associated with inferior clinical outcomes compared with luminal A cancers with high PR expression [46]. The gene discussed is ESR1; the disease is breast cancer.